Bavarian Nordic — Marts 2020
-
@Radar: er det fordig der står "they continue to hold..." Eller hvor ser du det henne?
-
"Jeg mangler stadig at se, at de har sendt ansøgningen afsted, inden jeg hæver mine arme." Altså en ansøgning til at starte fase 3 kommer nok først om et halvt år. Ansøgning til markedsgodkendelse kommer jo efter fase 3 - så du kan holde armene nede de næste par år
-
BAVA - vedr. den meddelelse der sendtes ud i går om J&Js andel. Jeg tolker den som om at J&J er gået under 5% fordi de ikke har udnyttet deres tegningsretter. Altså et negativt signal. Desværre.
-
ZEAL - Bryan Garnier har udsendt en kommentar i dag http://prntscr.com/rpzunw
-
FV (fair value) er ikke meget over dagens kurs
-
Copenhagen, March 31, 2020 In reference to Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) company announcement 09/2020 published March 26, 2020, regarding a private placement and directed issue of 741,816 new shares of the company (the New Ordinary Shares), Zealand Pharma A/S (Zealand) announces that it has today increased its share capital by DKK 741,816, divided into 741,816 New Ordinary Shares with a nominal value of DKK 1 each.
-
The gross proceeds from the issuance of the New Ordinary Shares amounts to DKK 137,236,000.
Following the registration of the New Ordinary Shares with the Danish Business Authority, Zealands share capital amounts to DKK 36,887,952 divided into 36,887,952 shares with a nominal value of DKK 1 each.
-
The New Ordinary Shares have been issued today and are expected to be admitted to trading on Nasdaq Copenhagen on April 1, 2020 in Zealands permanent ISIN code DK0060257814.
The amendments to Zealands articles of association required by the capital increase have been registered today with the Danish Business Authority.
-
Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal Rescue Pen for treatment of severe hypoglycemia
The Dasiglucagon HypoPal Rescue Pen New Drug Application represents a major milestone in Zealand Pharmas efforts to bring life changing therapies to people with diabetes
-
The submission encompasses three Phase 3 trials which met all primary and key secondary endpoints with a median time to recovery from hypoglycemia of only 10 minutes
Zealand Pharma remains on-track to build commercial infrastructure in the U.S. for the anticipated Dasiglucagon HypoPal Rescue Pen launch in 2021
-
Hypopal anvendes til nødbehandling af diabetikere i forbindelse med for lavt blodsukkerniveauer.
Pennen er baseret på lægemiddelkandidaten Dasiglucagon, der skal bruges til behandling af episoder med for lavt blodsukker hos diabetikere - såkaldt hypoglykæmi.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind